IML represents 64 research-based pharmaceutical companies operating in Luxembourg. Our members are committed to researching, developing, and bringing to patients new medicines that improve health and the quality of life. Our association supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe.
IIM
IML - Innovative Medicines for Luxembourg
Industry association · Luxembourg
2
positions filed
in the 665 files tracked
1
legislative file
of 665 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,800 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Track IML in PolicySpeak: request access →
Work at IML - Innovative Medicines for Luxembourg? so we know who speaks for it.
Their record over time
IML - Innovative Medicines for Luxembourg filed 2 positions on 17 Oct 2023, across 1 of the 665 legislative files tracked here.
What they argued
IML represents 64 research-based pharmaceutical companies operating in Luxembourg. Our members are committed to researching, developing, and bringing to patients new medicines that improve health and the quality of life. Our association supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put IML - Innovative Medicines for Luxembourg next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from IML - Innovative Medicines for Luxembourg’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.